Owens, Dominic D. G. https://orcid.org/0000-0001-6194-4636
Maitland, Matthew E. R.
Khalili Yazdi, Aliakbar
Song, Xiaosheng https://orcid.org/0000-0003-0454-186X
Reber, Viviane https://orcid.org/0000-0001-7653-6918
Schwalm, Martin P. https://orcid.org/0000-0002-1252-1829
Machado, Raquel A. C. https://orcid.org/0000-0001-5912-2991
Bauer, Nicolas https://orcid.org/0009-0004-3448-9796
Wang, Xu
Szewczyk, Magdalena M.
Dong, Cheng https://orcid.org/0000-0002-2891-8759
Dong, Aiping
Loppnau, Peter
Calabrese, Matthew F. https://orcid.org/0000-0002-9394-3686
Dowling, Matthew S.
Lee, Jisun https://orcid.org/0000-0003-1750-0063
Montgomery, Justin I.
O’Connell, Thomas N.
Subramanyam, Chakrapani
Wang, Feng
Adamson, Ella C.
Schapira, Matthieu https://orcid.org/0000-0002-1047-3309
Gstaiger, Matthias https://orcid.org/0000-0002-3245-3253
Knapp, Stefan https://orcid.org/0000-0001-5995-6494
Vedadi, Masoud
Min, Jinrong https://orcid.org/0000-0001-5210-3130
Lajoie, Gilles A.
Barsyte-Lovejoy, Dalia https://orcid.org/0000-0002-6560-9621
Owen, Dafydd R. https://orcid.org/0000-0003-3106-7809
Schild-Poulter, Caroline https://orcid.org/0000-0001-9943-9942
Arrowsmith, Cheryl H. https://orcid.org/0000-0002-4971-3250
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (FDN154328, MOP-142414, PJT-169101)
Mitacs Elevate Postdoctoral Fellowship
Deutsche Forschungsgemeinschaft (CRC1430)
EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (RGPIN-2021-02728, RGPIN-2021-03435)
Cancer Research Society (25418)
Article History
Received: 17 January 2023
Accepted: 12 April 2024
First Online: 21 May 2024
Competing interests
: M.F.C., M.S.D., J.L., J.I.M., T.N.O., C.S., F.W. and D.R.O. are or were employees of Pfizer and some of the authors are shareholders in Pfizer Inc. After submission, D.D.G.O. became an employee of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. The remaining authors declare no competing interests.